Company: SISI
Filing Date: 2025-06-23
Form Type: 8-K
Source: 0001641172-25-016061
Chunk: 0

Company: SHINECO, INC.
Filing Date: 2025-06-23
Form: 8-K
Item: Item 2.01
Chunk 0
---
Item
2.01 Completion of Acquisition or Disposition of Assets

On
June 18, 2025 (the “ Closing Date”), Shineco Life Science Group Hong Kong Co., Limited (“ Shineco Life Science”),
a subsidiary of Shineco, Inc. (the “ Company”), closed the acquisition of 51% of the equity interests in InfiniClone Limited,
a company limited by shares incorporated in Hong Kong (“ InfiniClone”), pursuant to the share purchase agreement (the “ SPA”)
dated April 22, 2025 with Dr. Lim Kah Meng, the sole shareholder of InfiniClone (the “ Seller”). On or prior to the Closing
Date, the closing conditions as set forth in the SPA were satisfied or otherwise waived by the parties thereto, and the Seller has transferred
51% of the equity interests in InfiniClone to Shineco Life Science; therefore, InfiniClone became a direct subsidiary of Shineco Life
Science. In exchange, Shineco Life Science paid to the Seller US$19,895,600 in cash and the Company issued 3,450,000 shares of the Company’s
common stock, par value $0.001 per share (the “ Shares”).

The
Shares were issued in reliance on Rule 902 of Regulation S promulgated under the Securities Act of 1933, as amended, and the Seller represented
that he was not a resident of the United States or a “ U. S. person” as defined in Rule 902(k) of Regulation S and was not
acquiring the Shares for the account or benefit of any U. S. person.

A
copy of the SPA is filed as Exhibit 2.1 hereto and is incorporated herein by reference. The above description of the SPA is qualified
in its entirety by reference to such exhibit.

Item
3.02 Unregistered Sales of Equity Securities